mezigdomide (CC-92480) - BMS
Characterization of the IKZF1 Interactome in Multiple Myeloma and Its Modulation by CELMoDs (IMS 2026) - Sep 11, 2026 - Abstract #PA-073; Pres time: Sep 23, 2026; " IKZF1 interactors were identified using TurboID proximity labeling in MM.1S cells expressing IKZF1-TurboID or nuclear (NLS-)TurboID controls, followed by mezigdomide treatment with proteasome inhibitor, streptavidin enrichment, and LC-MS analysis... This study provides the first comprehensive map of the IKZF1 interactome in MM, integrating proximity labeling and functional genomics. We reveal extensive, MM-specific IKZF1 interactions and a network of NF-κB regulators associated with IKZF1, suggesting crosstalk between IKZF1 regulation and NF-κB signaling under CELMoD treatment. These findings may inform strategies to overcome drug resistance." 
IO biomarker • Hematological Malignancies • Inflammation • Multiple Myeloma • CCND2 • CD40 • CRBN • DDB1 • IKZF1 • IKZF3 • IL17RB • MCL1 • NFKBIE • PRDM1 • RELA • TNFA • TNFAIP3
https://imsannual2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=TU1XRFNPTlIyMjY0Nw&PosterID=826478&rnd=0.5338731
 
Jing Fu1; Josefine Krueger2; Shirong Li2; Guifen Liu2; Yuen Lam Dora Ng3; Jan Krönke4; Suzanne Lentzsch2
 
Sep 11, 2026
 
Prev Next